Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease
Molecules · 2026
DOI: 10.3390/molecules31030474 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Junshuai Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Protease Inhibitors, Coronavirus 3C Proteases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: R&D Program of Beijing Municipal Education Commission, Science and technology project of Henan Province, Henan Provincial International Science and Technology Cooperation Project.
Abstract (Originalsprache)
Papain-like protease (PLpro), a crucial functional domain of the SARS-CoV-2 non-structural protein 3 (nsp3), plays a dual role in both hydrolyzing viral polyprotein precursors and modulating host immune responses. These critical functions position PLpro as a key target in the ongoing development of antiviral therapies for SARS-CoV-2. This review analyzes more than 100 PLpro-ligand co-crystal structures and summarizes the major binding modes between these ligands and PLpro. Most of these ligands bind to sites analogous to those targeted by the classical non-covalent inhibitor GRL0617, primarily involving the P3 and P4 subsites and the BL2 loop. Based on these structural insights, optimized inhibitors have expanded targeting beyond the canonical binding site to auxiliary regions such as the BL2 groove and the Val70 site, and in some cases toward the catalytic Cys111 buried within a narrow pocket. Certain ligands identified through various screening approaches bind to non-canonical or allosteric regions, such as the S1 and S2 sites or the zinc-finger domain, engaging PLpro through distinct interaction modes and thereby offering additional opportunities for PLpro inhibitor design. The review also discusses potential strategies for future PLpro inhibitor development informed by recent structural advances. Taken together, these structural and functional insights support ongoing efforts in the structure-guided design and optimization of PLpro inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.
- Beijing Synchrotron Radiation Facility, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China.
- Railway Food Safety Management Engineering Technology Research Center, Zhengzhou Railway Vocational & Technology College, Zhengzhou 451400, China.
- Institute of Matter Science, Beijing University of Technology, Beijing 100124, China.
ORCID-Profile: Yuancong Xu, Yubai Zhou, Peng Cao, Yong Gong
Förderung
- R&D Program of Beijing Municipal Education Commission
- Science and technology project of Henan Province
- Henan Provincial International Science and Technology Cooperation Project
Zitieren
APA
Wang, J., Xu, Y., Yang, Y., Zhang, B., Chen, S., Li, Z., Zhu, H., Yang, H., Wang, H., Zhou, Y., Cao, P., Zhai, B., & Gong, Y. (2026). Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease. Molecules. https://doi.org/10.3390/molecules31030474
Vancouver
Wang J, Xu Y, Yang Y, Zhang B, Chen S, Li Z, et al. Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease. Molecules. 2026. doi:10.3390/molecules31030474
BibTeX
@article{Wang2026,
author = {Wang, Junshuai and Xu, Yuancong and Yang, Yishu and Zhang, Botao and Chen, Sixu and Li, Zhaoyang and Zhu, Haojia and Yang, Huai and Wang, Hongtao and Zhou, Yubai and Cao, Peng and Zhai, Baiqiang and Gong, Yong},
title = {Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31030474}
}
EUVIMED